Biosimilar mAbs are complex molecules that have highly similar therapeutic and physic -ochemical properties to innovator, or originator biologicals such as blockbuster therapies adalimumab (Humira) from Abbott, infliximab (Remicade) from Johnson & Johnson and trastuzumab (Herceptin) from Roche.
展开▼
